PDCD1 and neoplasm: According to the CheckMate 057 results [24], our work also demonstrated that tumor PD-L1 expression at the lowest IHC cut-off of 1%, significantly correlated with anti-PD-1/PD-L1 MoAbs activity in pre-treated NSCLC patients, confirming its potential role as predictive biomarker for clinical use.